Role of Zidovudine and Candesartan combination in novel SARS-CoV-2 management, prophylaxis and treatment trials | ||||
| Al-Azhar University Journal of Virus Researches and Studies | ||||
| Article 1, Volume 2, Issue 1, 2020, Page 1-6 PDF (512.08 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/AUJV.2020.106719 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mohamed A. Mostafa
| ||||
| Faculty of Pharmacy, Mansoura University. | ||||
| Abstract | ||||
| The coronavirus disease 19 (COVID-19) is a highly communicable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which raised in Wuhan, China and stretch around the humankind. Genomic analysis exposed that SARS-CoV-2 is phylogenetically associated to severe acute respiratory syndrome-like (SARS-like) bat viruses, hence bats could be the possible primary reservoir. The intermediate obtain of beginning and relocation to humans is not known, however, the rapid human to human transfer has been confirmed commonly. There is no clinically approved antiviral drug or vaccine available to be used against COVID-19. However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical trials, resulted in clinical recovery. In the current review, we summarize the possibility to use Zidovudine as antiviral drug and Candesartan as Angiotensin II Receptor Blocker (ARB) on the basis Zidovudine works as RNA reverse transcriptase inhibitor (RTI) and Candesartan as ARB, the receptors that bind to the spike protein (S-protein) present in the surface or coronavirus. | ||||
| Keywords | ||||
| Coronavirus; SARS-CoV-2; COVID-19; RTIs; ARB; ACE Inhibitors; Candesartan cilexetil; Zidovudine | ||||
|
Statistics Article View: 266 PDF Download: 251 |
||||
